Deferasirox

Chemical formula: C₂₁H₁₅N₃O₄  Molecular mass: 373.362 g/mol  PubChem compound: 5493381

Therapeutic indications

Deferasirox is indicated for:

Chronic iron overload due to frequent blood transfusions in anaemia syndromes

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Deferasirox is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.

Deferasirox is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:

  • in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,
  • in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged 2 years and older,
  • in adult and paediatric patients with other anaemias aged 2 years and older.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Chronic iron overload in non-transfusion-dependent thalassaemia syndromes

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Deferasirox is indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Deferasirox is contraindicated in the following cases:

Moderate renal impairment, severe renal impairment

at least one of



Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Severe hepatic impairment

Hepatic failure stage IV

Iron chelator therapies

at least one of
Deferoxamine
Deferiprone

Aluminium-containing antacid preparations

at least one of
Aluminium compounds
Combinations and complexes of aluminium, calcium and magnesium compounds

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2022: EXJADE Film-coated tablet
Structured Product Labeling (SPL/PLR) 2020: JADENU Film-coated tablet / Granules
Summary of Product Characteristics (SPC) 2022: EXJADE Granules in sachet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈